SCHEMBL477106

SCHEMBL477106

CNc1cc(-c2c(C)nc3ccc(Cl)nn23)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.47
WDR77 Q9BQA1 1/20 0.47
CSNK1E P49674 1/20 0.40
DYRK1A Q13627 3/20 0.38
CLK2 P49760 1/20 0.38
HASPIN Q8TF76 1/20 0.38
MAPT P10636 1/20 0.37
PI4KB Q9UBF8 3/20 0.36
MAPK13 O15264 6/20 0.35
MAPK12 P53778 6/20 0.35
MAPK11 Q15759 6/20 0.35
MAPK14 Q16539 6/20 0.35
ROCK2 O75116 1/20 0.34
ROCK1 Q13464 1/20 0.34
CDC42BPB Q9Y5S2 1/20 0.34
PIK3C3 Q8NEB9 1/20 0.34
GRM2 Q14416 1/20 0.33
SYK P43405 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3R1 P27986 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL477188 0.86 PRMT5 (0.45) PRMT5WDR77CSNK1EMAPK13MAPK12
SCHEMBL477168 0.85 PRMT5 (0.49) PRMT5WDR77CSNK1EDYRK1ACLK2
SCHEMBL477098 0.82 PRMT5 (0.49) PRMT5WDR77CSNK1EDYRK1ACLK2
SCHEMBL10224023 0.81 TGFBR1 (0.47) PRMT5WDR77DYRK1ACLK2HASPIN
SCHEMBL477039 0.80 PRMT5 (0.45) PRMT5WDR77CSNK1EDYRK1ACLK2
SCHEMBL477105 0.80 PRMT5 (0.55) PRMT5WDR77CSNK1EDYRK1ACLK2
SCHEMBL10223832 0.78 CSNK1E (0.56) PRMT5WDR77CSNK1EDYRK1ACLK2
SCHEMBL477158 0.77 PRMT5 (0.46) PRMT5WDR77DYRK1AMAPTPI4KB
SCHEMBL477166 0.76 CSNK1E (0.50) CSNK1EDYRK1ACLK2HASPINMAPT
SCHEMBL477167 0.76 CSNK1E (0.50) CSNK1EDYRK1ACLK2HASPINMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331546-B1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2012-02-01 EP disclosed
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-12-22 US disclosed
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-12-22 US disclosed
EP-2331546-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF Sanofi-aventis (FR) 2011-06-15 EP disclosed
WO-2010018327-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF NR3C1, CNKSR1, NR3C2 PRMT5 388/4885WDR77 1353/4885CSNK1E 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.